Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebszentrums

Zusammenfassung

Hintergrund ABP 980 ist ein biosimilarer Antikörper von Referenz-Trastuzumab (RTZ). Ziel dieser Studie war es, die Ähnlichkeit von ABP 980 mit RTZ zu bestätigen in Bezug auf die klinische Wirksamkeit und Sicherheit in Patientinnen mit HER2-positivem Brustkrebs im Frühstadium, die sich einer neoadjuvanten Chemotherapie mit Trastuzumab unterziehen. Die Studie sollte reale klinische Bedingungen abbilden und schloss somit auch Patientinnen ein, die Pertuzumab erhielten.

Methoden Patientinnen mit HER2-positivem Brustkrebs im Frühstadium, die zwischen 12/2010 und 03/2020 in der Frauenklinik des Universitätsklinikums Tübingen, Deutschland, mindestens 4 Zyklen einer neoadjuvanten Chemotherapie (+/− Pertuzumab) in Kombination mit ABP 980 oder RTZ erhielten, wurden in diese retrospektive Analyse aufgenommen. Für die Wirksamkeitsanalyse wurden Patientinnen mit pathologischer Komplettremission (pCR = kein invasiver Tumor in der Brust und negativer Lymphknotenstatus) verglichen. Zur Beurteilung der Sicherheit von ABP 980 wurde die Anzahl an Patientinnen, die eine Minderung ihrer linksventrikulären Funktion (LVEF) von mehr als 10% aufwiesen, verglichen.

Ergebnisse Insgesamt wurden 124 Patientinnen in die Studie aufgenommen. Davon erhielten 46 (37,1 %) Frauen ABP 980, und 77 (62,9 %) Patientinnen wurden mit RTZ behandelt. Eine pCR stellte sich bei 77 (62,1 %) Patientinnen ein. Es gab keinen signifikanten Unterschied bezüglich der klinischen Wirksamkeit zwischen mit ABP 980 behandelten Patientinnen und den mit RTZ behandelten Patientinnen (die jeweiligen pCR-Raten betrugen 60,9% bzw. 62,8 %, p = 0,829), auch nicht in Bezug auf die kardiologische Sicherheit (eine LVEF-Minderung wurde bei 6,5% bzw. 2,6% der Fälle vermerkt, p = 0,274).

Schlussfolgerung Die Ähnlichkeit von ABP 980 und RTZ in einer realen klinischen Situation, die auch eine große Anzahl an mit Pertuzumab behandelten Patientinnen einschloss, konnte bestätigt werden.

Abstract

Background ABP 980 is a biosimilar antibody to reference trastuzumab (RTZ). Aim of the following study is to confirm the similarity of ABP 980 and RTZ in terms of clinical efficacy and safety in patients with HER2-positive early breast cancer (EBC) undergoing neoadjuvant trastuzumab-containing chemotherapy in a clinical real-world situation that also includes patients receiving pertuzumab.

Methods Patients with HER2-positive EBC, who were treated from 12/2010 to 03/2020 at the Department of Women’s Health at Tuebingen University Hospital, Germany, with at least four cycles of neoadjuvant chemotherapy (+/− pertuzumab) in combination with ABP 980 or RTZ were included in a retrospective analysis. For efficacy analysis patients achieving a pathologic complete remission (pCR = no invasive tumor in breast and lymph nodes) were compared. Safety was evaluated by comparing the number of patients with a decrease in left ventricular function (LVEF) of > 10%.

Results 124 patients were included of whom 46 (37.1 %) have received ABP 980 and 77 (62.9%) were treated with RTZ. A pCR was found in 77 patients (62.1 %). For patients treated with ABP 980 as compared to RTZ, there was no significant difference regarding efficacy (pCR-rates of 60.9% versus 62.8 %, p = 0.829) or cardiac safety (LVEF decline in 6.5% versus 2.6 %, p = 0.274).

Conclusion Similarity of ABP 980 as compared to RTZ was confirmed in a real-world situation, including a large proportion of patients that have also received pertuzumab treatment.

Keywords

trastuzumab - biosimilar - primary systemic therapy - pathological complete response

Schlüsselwörter

Trastuzumab - Biosimilar - primäre systemische Therapie - pathologische Komplettremission

Publication History

Article published online:
23 May 2024

• Literatur

• 1 Slamon D, Clark G, Wong S. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
• 2 Press MF, Bernstein L, Thomas PA. et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-2904
• 3 Piccart-Gebhart MJ, Procter M, Leyland-Jones B. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672
• 4 Romond EH, Perez EA, Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684
• 5 Slamon D, Eiermann W, Robert N. et al. Adjuvant Trastuzumab in HER2- Positive Breast Cancer. N Engl J Med 2011; 365: 1273-1283
• 6 Slamon DJ, Leyland-Jones B, Shak S. et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
• 7 Marty M, Cognetti F, Maraninchi D. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005; 23: 4265-4274
• 8 Untch M, Fasching PA, Konecny GE. et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: Results from the TECHNO Trial of the AGO and GBG study groups. J Clin Oncol 2011; 29: 3351-3357
• 9 Schneeweiss A, Fasching PA, Fehm T. et al. AGO Algorithms for the Treatment of Breast Cancer: Update 2021. Geburtshilfe Frauenheilkd 2021; 81: 1101-1111
• 10 Thomssen C, Fehm TN, Stickeler E. et al. Update Breast Cancer 2021 Part 4 – Prevention and Early Stages. Geburtshilfe Frauenheilkd 2022; 82: 206-214
• 11 Tesch H, Müller V, Wöckel A. et al. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1115-1122
• 12 Buzdar AU, Ibrahim NK, Francis D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685
• 13 Gianni L, Eiermann W, Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384
• 14 Cortazar P, Zhang L, Untch M. et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014; 384: 164-172
• 15 von Minckwitz G, Huang CS, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628
• 16 Swain SM, Miles D, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519-530
• 17 von Minckwitz G, Procter M, de Azambuja E. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017; 377: 122-131
• 18 Schneeweiss A, Chia S, Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284
• 19 Gianni L, Pienkowski T, Im YH. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
• 20 European Medicines Agency. Similar biological medicinal products. Accessed March 18, 2021 at: https://www.ema.europa.eu/en/similar-biological-medicinal-products
• 21 Declerck P, Farouk Rezk M. The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Rheumatology (Oxford) 2017; 56: iv4-iv13
• 22 Weise M, Bielsky MC, De Smet K. et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-5117
• 23 Barbier L, Declerck P, Simoens S. et al. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer 2019; 121: 199-210
• 24 Stebbing J, Mainwaring PN, Curigliano G. et al. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. J Clin Oncol 2020; 38: 1070-1080
• 25 Hanes V, Chow V, Zhang N. et al. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol 2017; 79: 881-888
• 26 Kolberg HC, Colleoni M, Santi P. et al. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Target Oncol 2019; 14: 647-656
• 27 von Minckwitz G, Colleoni M, Kolberg HC. et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 2018; 19: 987-998
• 28 Hester A, Gaß P, Fasching PA. et al. Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres. Geburtshilfe Frauenheilkd 2020; 80: 924-931
• 29 AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2021. Accessed July 27, 2021 at: https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma
• 30 Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. Hoboken: Wiley; 2013
• 31 Hanes V, Chow V, Zhang N. et al. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol 2017; 79: 881-888
• 32 Swain SM, Ewer MS, Viale G. et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2018; 29: 646-653
• 33 Fasching PA, Hartkopf AD, Gass P. et al. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Res Treat 2019; 173: 319-328
• 34 Lidbrink E, Chmielowska E, Otremba B. et al. A real-world study of cardiac events in 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat 2019; 174: 187-196
• 35 Sherman RE, Anderson SA, Dal Pan GJ. et al. Real-World Evidence – What Is It and What Can It Tell Us?. N Engl J Med 2016; 375: 2293-2297
• 36 Pivot X, Bondarenko I, Nowecki Z. et al. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol 2018; 36: 968-974
• 37 Stebbing J, Baranau Y, Baryash V. et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, doubleblind, active-controlled, phase 3 equivalence trial. Lancet Oncol 2017; 18: 917-928
• 38 Lammers PE, Dank M, Masetti R. et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer 2018; 119: 266-273
• 39 Pegram MD, Bondarenko I, Zorzetto MMC. et al. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. Br J Cancer 2019; 120: 172-182
• 40 Rugo H, Barve A, Waller CF. et al. Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab. Ann Oncol 2016; 27: vi555